Challenges facing vaccine producers include: different technology platforms make it difficult to standardize facility design and equipment; unique facility and equipment may be required for an individual vaccine or class of vaccines, and finally, many vaccines are typically low volume with high throughput products. In conclusion, there is no â€˜one-size fits all' facility for all vaccine products and processes!
Susan Dana Jones, Vice President and Senior Consultant, BioProcess Technology Consultants, joined us at the World Vaccine Cell Culture Congress 2012 in Washington to discuss single use products for bio production. Some advantages of single-use technologies for vaccines include: improved return on capital; reduced process equipment complexity; reduced facility complexity and cost, and new systems offering low shear mixing and process scalability for improved yields and product quality. Not only did she discuss the previous mentioned challenges facing vaccine production, but she further detailed the difficulties concerning manufacturing, for example, the fact that many vaccines are multi-strain in form.
Why not download the full presentation and discover more about single use products for bioproduction: available options for cell culture and downstream processing.